Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concurrent panitumumab, cisplatin, and pelvic radiotherapy for primary cervical cancer (phase II, KRAS-stratified)
2009-012453-38Phase 2Terminated
- Sponsor
- AGO Austria
- Start
- Jul 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panitumumab in Cervical Cancer (CC), sponsored by AGO Austria. Primary endpoints: Tumor response rate of the uterine target lesion, Progression-free survival of target lesion at 4 months and 1 more. Started Jul 2009; status: terminated.
02
Drugs
panitumumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on 2009-012453-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012453-38.